Sutro Biopharma Long Term Debt 2017-2022 | STRO

Sutro Biopharma long term debt from 2017 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Sutro Biopharma Annual Long Term Debt
(Millions of US $)
2021 $16
2020 $25
2019 $9
2018 $10
2017 $
2016 $
Sutro Biopharma Quarterly Long Term Debt
(Millions of US $)
2022-03-31 $13
2021-12-31 $16
2021-09-30 $19
2021-06-30 $22
2021-03-31 $25
2020-12-31 $25
2020-09-30 $24
2020-06-30 $24
2020-03-31 $24
2019-12-31 $9
2019-09-30 $6
2019-06-30 $7
2019-03-31 $9
2018-12-31 $10
2018-09-30 $12
2018-06-30
2018-03-31
2017-12-31
2017-09-30
2016-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.246B $0.062B
Sutro Biopharma Inc. develops and manufactures pharmaceutical products. The Company provides antibody drug conjugate and multi-specific antibody-based therapeutics for cancer therapy. Its product pipeline consists of STRO-001 and STRO-002 which are in clinical stage. Sutro Biopharma Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $163.597B 9.95
Bio-Rad Laboratories (BIO.B) United States $14.907B 32.33
QIAGEN (QGEN) Netherlands $10.865B 17.15
Biohaven Pharmaceutical Holding (BHVN) United States $10.248B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.228B 0.00
Arcus Biosciences (RCUS) United States $1.901B 48.18
Emergent Biosolutions (EBS) United States $1.599B 6.85
Myovant Sciences (MYOV) United Kingdom $1.236B 0.00
Zymeworks (ZYME) Canada $0.320B 0.00
Gelesis Holdings (GLS) United States $0.114B 0.00
Enzo Biochem (ENZ) United States $0.104B 0.00
Ambrx Biopharma (AMAM) United States $0.103B 0.00
SQZ Biotechnologies (SQZ) United States $0.087B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00